Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: Review Underway For Linhaliq, New Uses Of Lenvima, Cimzia; New Cycle Starts For Lutathera

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

You may also be interested in...



Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict

The latest drug development news and highlights from our US FDA Performance Tracker. 

Lutathera Approval Positions Novartis To Regain NET Share Taken By Ipsen

The US FDA has approved Advanced Accelerator Applications' radiopharmaceutical Lutathera to treat GEP-NETs second time around, just four days after Novartis closed its acquisition of AAA. The product should help the Swiss firm regain ground its Sandostatin product has lost to Ipsen's Somatuline.

Keeping Track: Shutdown Edition

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS121217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel